Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 amp TP53 wild-type |
Therapy | BI 907828 |
Indication/Tumor Type | intrahepatic cholangiocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 amp TP53 wild-type | intrahepatic cholangiocarcinoma | predicted - sensitive | BI 907828 | Case Reports/Case Series | Actionable | In a Phase Ia/Ib trial, BI 907828 treatment resulted in a partial response in a patient with MDM2-amplified (CN=9), TP53 wild-type metastatic intrahepatic cholangiocarcinoma, with treatment lasting 12 months (PMID: 38567193; NCT03449381). | 38567193 |
PubMed Id | Reference Title | Details |
---|---|---|
(38567193) | Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series. | Full reference... |